Personal and health care giant Johnson & Johnson has announced plans to acquire privately-held Aragon Pharmaceuticals in a deal that could reach $1 billion, according to reports. The acquisition is a strategic move for Johnson & Johnson into the market for pharmaceutical drugs that specialize in fighting diseases caused and driven by hormones. Reports say the deal between the parties includes a $650 million payment upfront as well as payments of $350 million in increments as the company reaches certain milestones. Aragon will reportedly separate the rest of its assets into a new business. Aragon is currently in the mid-stage of development of a drug to fight prostate cancer. The deal is expected to close in the third quarter of the year.
Featured News
Importers Sue Shipping Container Makers Over Alleged Price-Fixing Scheme
Jun 10, 2026 by
CPI
Brazil Fines Denso $19.5 Million for Role in Auto Parts Cartel
Jun 10, 2026 by
CPI
UK Competition Watchdog Opens Formal Review of Paramount Skydance-Warner Bros Discovery Deal
Jun 10, 2026 by
CPI
New York’s Synthetic Performer Disclosure Law Raises Compliance Stakes for Advertisers
Jun 10, 2026 by
CPI
Congress Weighs How Colleges Should Handle AI
Jun 10, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – (Geo)Political Antitrust
May 28, 2026 by
CPI
Competition Policy in Turbulent Geopolitical Times
May 28, 2026 by
Christophe Carugati & Annabelle Gawer
The New Political Determinants of U.S. Antitrust Policy
May 28, 2026 by
Aziz Z. Huq
The Geopolitical Rewiring of Antitrust
May 28, 2026 by
Hayane C. Dahmen
Three Strikes Against Political Antitrust
May 28, 2026 by
Nolan McCarty & Sepehr Shahshahani